Trump announces 100% chip tariff as Apple ups U.S. investment
In a recent 8-K filing, Tharimmune, Inc., a micro-cap biotech company with a market capitalization of $4.23 million, disclosed significant changes to its executive team and the establishment of new compensatory arrangements. The company’s stock has faced significant headwinds, declining over 54% in the past year according to InvestingPro data. Effective immediately, Randy Milby has stepped down from his roles as Chief Executive Officer (CEO) and member of the Board of Directors due to personal reasons. As part of a settlement and general release agreement, Milby will receive a payment of $133,500 upon the company securing a minimum of $3 million in financing. Additionally, his unvested stock options will vest immediately. InvestingPro analysis indicates the company maintains a weak financial health score of 1.35, with current financial obligations exceeding liquid assets.
Concurrently, the company appointed Sireesh Appajosyula as the new CEO. Appajosyula’s employment agreement mirrors that of Vincent LoPriore, who was named Executive Chairman of the Board on May 9, 2025. LoPriore’s five-year employment agreement, effective June 11, 2025, includes a base salary of $285,000 per year, potential for an annual bonus, eligibility for equity-based awards, and other benefits.
If LoPriore’s employment is terminated by the company without cause or if he resigns for good reason, he will receive continued base salary and health benefits for 12 months, among other benefits. All unvested equity awards will be fully vested, and stock options will remain exercisable for up to 60 months post-termination or until their expiration.
Additionally, James Gordon Liddy has been appointed to the Board of Directors, effective immediately. There are no reported family relationships or material interest transactions involving Appajosyula or Liddy requiring disclosure under SEC regulations.
These executive changes and agreements were filed with the SEC and are part of the company’s regulatory disclosures. With analysts projecting continued losses for the fiscal year 2025 and a current price significantly below its 52-week high of $6.39, investors seeking deeper insights into Tharimmune’s financial health can access additional analysis and 8 more exclusive ProTips through InvestingPro.
In other recent news, Tharimmune, Inc. has made significant advancements in its drug development and corporate governance. The company released promising Phase 1 study data for TH104, a drug designed for opioid exposure prophylaxis. The study showed TH104’s buccal film formulation has a distinct metabolic profile and comparable safety to intravenous nalmefene, with the FDA indicating that no further clinical trials may be needed before a New Drug Application submission. Additionally, Tharimmune expanded its Board of Directors by appointing Clay Kahler and Gary Stetz, reflecting its commitment to strengthening governance as it advances its clinical programs.
In a strategic leadership change, Vincent LoPriore has been appointed as the new Executive Chairman of Tharimmune’s Board of Directors, succeeding Randy Milby. This appointment is part of the company’s efforts to enhance its leadership amid ongoing growth. The company also received positive feedback from the FDA regarding TH104, positioning it as a potential countermeasure for high-potency opioid threats, such as fentanyl. These developments underscore Tharimmune’s focus on addressing national security concerns and advancing its portfolio, which includes treatments for autoimmune diseases and solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.